The POSITIVE Phase IV Study: Interim 52-Week Results on Patient Well-Being With Tildrakizumab
Psoriatic disease extends beyond the skin, imposing a significant psychosocial burden, often leading to embarrassment, social withdrawal…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.